NEW YORK (GenomeWeb News) – Roche Diagnostics and Danish firm Exiqon have amended their 2005 licensing agreement covering the Universal ProbeLibrary, which is based on Exiqon’s Locked Nucleic Acid oligonucleotides.
Roche said that its exclusive rights to sell and distribute the ProbeLibrary products have been extended on a co-exclusive basis. It also gained co-exclusive rights to use the ProbeLibrary in developing and manufacturing its new line of RealTime ready qPCR assays, which are gene expression assays that can run in a single assay format or in a multiwell plate format on its LightCycler System.
The partners did not disclose the length of the new contract or provide financial terms of the amended pact.
“We will address the need for increased speed and flexibility in biomedical research providing customized on demand supply of single assays and ready to use qPCR panels for virtually every gene of the human genome and other important organisms,” Manfried Baier, head of Roche Applied Science, a business area within Roche Diagnostics, said in a statement.